The global single use bioreactors single use bioreactors market was valued at USD 4.85 billion in 2025. The market is projected to grow from USD 5.58 billion in 2026 to USD 17.07 billion by 2034, exhibiting a compound annual growth rate of 14.99% during the forecast period. Contrive Datum Insights presents this information in its report titled "Single Use Bioreactors Market Size, Share & Industry Analysis, By Product scope (Up to 10L, 11-100L, 101-500L, 501-1500L, Above 1500L, 2D Bags, 3D Bags, Others, Other Products), Type (Stirred-tank SUBs, Wave-induced SUBs, Bubble-column SUBs, Other SUBs), Type of cell (Mammalian Cells, Bacterial Cells, Yeast Cells, Other Cells), Molecule type (Monoclonal Antibodies, Vaccines, Gene Modified Cells, Stem Cells, Other Molecules), Application (Research and Development (R&D) or Process Development, Bioproduction), End-use (Pharmaceutical & Biopharmaceutical Companies, CROs & CMOs, Academic & Research Institutes), Usage type (Lab-scale Production, Pilot-scale Production, Large-scale Production), and Regional Forecast, 2026-2034".
A single-use bioreactor is a pre-sterilized, disposable vessel or bag, typically made from a multilayer plastic film, used to grow mammalian, bacterial or yeast cells for the production of biologic drugs and vaccines. It replaces a fixed stainless-steel tank that must be cleaned and re-validated between batches, and is supplied in capacity bands from benchtop research scale up to large commercial-production volumes. Buyers include pharmaceutical and biopharmaceutical manufacturers running their own production lines, contract development and manufacturing organizations producing on behalf of others, and academic and research laboratories developing new cell lines and processes.
Rising biologics and monoclonal antibody production volumes
Rising biologics and monoclonal antibody production volumes is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 14.99% a year, the product scope lines exposed to it move fastest: Above 1500L compounds at 20.14%, taking its share of revenue from 10.1% to 15% and its value from USD 0.49 billion to USD 2.56 billion.
A more favourable outcome is possible. If faster biosimilar and cell-and-gene-therapy approvals pull forward single-use capacity investment across all regions, and CDMO capital spending accelerates ahead of the base case, 2034 revenue reaches USD 19.12 billion instead of the USD 17.07 billion the base case carries.
The downside is specific. Biopharma capital spending tightens and facility expansions are delayed, slowing the shift away from stainless-steel systems and pushing large-capacity single-use adoption further out, and 2034 revenue lands at USD 15.02 billion. 101-500L is the drag, 19.79% of the 2025 base compounding at 14.33% while the market runs at 14.99%.
Key Players Compete on 101-500L Volume and Above 1500L Growth
The product scope axis, not the regional one, is what divides the field. 101-500L is the volume position, 19.79% of 2025 revenue at USD 0.96 billion, holding 18.98% through 2034, and it is defended by scale. Above 1500L is the growth position at 20.14%, and it is open. Strength in one does not carry into the other.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Stirred-tank SUBs | 54.85% · USD 2.66 billion | Wave-induced SUBs 16.29% |
| Type of cell | Mammalian Cells | 68.04% · USD 3.3 billion | — |
| Molecule type | Monoclonal Antibodies | 45.98% · USD 2.23 billion | Gene Modified Cells 21.14% |
| Application | Bioproduction | 71.96% · USD 3.49 billion | — |
| End-use | Pharmaceutical & Biopharmaceutical Companies | 62.06% · USD 3.01 billion | CROs & CMOs 17.1% |
| Usage type | Large-scale Production | 50.1% · USD 2.43 billion | — |
- Based on regional analysis, North America led the global single use bioreactors single use bioreactors market in 2025 with 41% of global revenue at USD 1.99 billion, reaching USD 6.15 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24% in 2025 to 32% in 2034, with revenue growing from USD 1.16 billion to USD 5.46 billion.
- At 2.5% of 2025 revenue and 2.5% by 2034, Middle East and Africa is the smallest region throughout.
- 101-500L was the leading product scope line in 2025, taking 19.79% of revenue at USD 0.96 billion.
- No product scope line grows faster than Above 1500L, at a projected 20.14%.
- The United States is the largest single country market at USD 1.69 billion in 2025, 34.8% of global revenue.
The report segments the market across seven axes; by product scope, and by type, type of cell, molecule type, application, end-use and usage type; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 15.02 billion and USD 19.12 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.